Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

118.14 -3.98 (-3.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Is BioNTech Stock a Buy Now?
Or is it too late to get in on the company after its coronavirus-related success? 
Via The Motley Fool
8 Analysts Have This to Say About BioNTech
Via Benzinga
Mohamed El-Erian On Yield And Oil Price Drop: Economic Boon Or Major Downturn Ahead?
Via Benzinga
BioNTech Se (BNTX) Q3 2023 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday
Eli Lilly jumped, while energy plays were big winners and losers. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Like Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic Fades
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. 
Via Benzinga
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
7 Undervalued Stocks That Analysts Love Right Now
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government Paid
The transition to the commercial market is planned for 2024 and could bolster sales. 
Via Investor's Business Daily
7 Stocks That Are Heading for a Train Wreck
There's always a bear market somewhere. Here are seven stocks to sell that investors should definitely unload now. 
Via InvestorPlace
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023
Via Benzinga
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves. 
Via Benzinga
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.  
Via Benzinga
Exposures COVID-19
Pfizer Cuts Annual Revenue Guidance By $9B Amid COVID-19 Vaccine Sales Slump, BioNTech Warns €900M Write-Offs
Friday, Pfizer Inc (NYSE: PFE) slashed its full-year earnings and revenue guidance, citing decreasing demand for its  
Via Benzinga
Exposures COVID-19
BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Cut Your Losses: Sell These 7 Weak Stocks Now
You can't let weakness in a company or the market damage your portfolio. Avoid disappointing returns by moving on these stocks to sell. 
Via InvestorPlace
Is Novavax Stock a Buy Now?
Is this company just a pandemic stock? 
Via The Motley Fool
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.